NDA 208025 · Dexcel
Lansoprazole
Lansoprazole · Oral · Proton Pump Inhibitor
Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jun 7, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
288
83 Phase 3, 12 recruiting
FAERS reports
107,664
99,937 serious, 13,581 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 2, 2026.
Use • treats frequent heartburn (occurs 2 or more days a week) • not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect
Therapeutic areas: Gastroenterology and liver
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- LANSOPRAZOLE · LANSOPRAZOLE 15MG · TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Lansoprazole" as an intervention, any sponsor and status, largest first.
- Helicobacter Eradication Aspirin TrialPivotal-lookingCompleted
University of NottinghamAcademic, hospital or other
NCT01506986 · 30,024 participants · Start Mar 2012 · Primary completion Oct 31, 2017
Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg; Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg · For: Gastrointestinal Ulcer Haemorrhage; Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Durham, United Kingdom · 6 sites in all
- Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General PopulationPivotal-lookingActive, not recruiting
National Cancer Center, KoreaGovernment (non-federal)
NCT02112214 · 5,224 participants (planned) · Start Jun 2014 · Primary completion Dec 2029
Drug: 10-day bismuth-based quadruple therapy · For: Gastric Cancer; Helicobacter Pylori Infection
Sites: Busan, South Korea; Chuncheon, South Korea; Daegu, South Korea · 11 sites in all
- Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive EsophagitisPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00251719 · 2,054 participants · Start Dec 2005 · Primary completion Jan 2007
Drug: Dexlansoprazole MR; Dexlansoprazole MR and 1 more · For: Esophagitis, Reflux; Esophagitis, Peptic
Sites: Anniston, Alabama; Hueytown, Alabama; Huntsville, Alabama · 144 sites in all
- Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive EsophagitisPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00251693 · 2,038 participants · Start Dec 2005 · Primary completion Jan 2007
Drug: Dexlansoprazole MR; Dexlansoprazole MR and 1 more · For: Esophagitis, Reflux; Esophagitis, Peptic
Sites: Alabaster, Alabama; Birmingham, Alabama; Huntsville, Alabama · 140 sites in all
- Prophylaxis for Aspiration of Gastric Contents.Pivotal-lookingCompleted
King Saud UniversityAcademic, hospital or other
NCT02703896 · 1,920 participants · Start Jan 2012 · Primary completion Jan 2012
Drug: Drug either PPIS or H2RA and prokinetics · For: Pulmonary Aspiration of Gastric Contents
- S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)Pivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT01061437 · 1,859 participants · Start Jun 2009 · Primary completion Jul 2011
Drug: PACx14; PACMx5 and 1 more · For: Helicobacter Pylori Infection
Sites: Santiago, Chile; Cali, Colombia; San José, Costa Rica · 7 sites in all
- Gastric Cancer Prevention in the Family Members by Helicobacter Pylori EradicationPivotal-lookingActive, not recruiting
National Cancer Center, KoreaGovernment (non-federal)
NCT01678027 · 1,838 participants · Start Nov 2004 · Primary completion Dec 2018
Drug: Placebo; LAC triple therapy · For: Gastric Cancer; Helicobacter Pylori Infection; Family Members
Sites: Goyang-si, South Korea
- Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With GoutPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT02139046 · 1,790 participants · Start Apr 2014 · Primary completion Nov 2015
Drug: Febuxostat IR; Febuxostat XR and 4 more · For: Gout
Sites: Binghamton, Alabama; Birmingham, Alabama; Huntsville, Alabama · 192 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea6,722
- dyspnoea6,053
- nausea5,778
- off label use5,446
- fatigue5,367
- vomiting5,281
- acute kidney injury5,012
- malaise4,796
- headache4,788
- chronic kidney disease4,679
- pyrexia4,606
- dizziness4,143
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,299 |
| 2005 | 1,407 |
| 2006 | 1,111 |
| 2007 | 1,295 |
| 2008 | 1,663 |
| 2009 | 1,688 |
| 2010 | 1,874 |
| 2011 | 2,666 |
| 2012 | 3,288 |
| 2013 | 2,962 |
| 2014 | 3,515 |
| 2015 | 4,950 |
| 2016 | 5,797 |
| 2017 | 5,516 |
| 2018 | 8,294 |
| 2019 | 10,604 |
| 2020 | 7,738 |
| 2021 | 6,769 |
| 2022 | 6,859 |
| 2023 | 7,552 |
| 2024 | 8,133 |
| 2025 | 7,421 |
| 2026 | 5,262 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lansoprazole (Lansoprazole)
2024 spending
$47.3M
Beneficiaries
324,506
1,231,347 claims
Per beneficiary
$146
$0.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $55,859,283 |
| 2021 | $62,952,966 |
| 2022 | $71,415,486 |
| 2023 | $57,025,404 |
| 2024 | $47,285,025 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD, Mégraud F, Laine L, et al. · Gastroenterology 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L, DeVault K, Katz P, et al. · Gastroenterology 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study.
Uemura N, Kinoshita Y, Haruma K, et al. · Clin Gastroenterol Hepatol 2025 · Clinical Trial, Phase IV, Multicenter Study
- Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K, Sakurai Y, Hori T, et al. · Aliment Pharmacol Ther 2016 · Comparative Study, Multicenter Study
- Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P, Katz PO, Chen Y, et al. · Am J Gastroenterol 2003 · Clinical Trial, Comparative Study
- Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y, Zhang S, Dai N, et al. · Gut 2020 · Clinical Trial, Phase III, Comparative Study
Sponsor: Dexcel
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.